Physician profile
Thomas B Leahey
NPI 1891886545
$11,663.80
in general payments reported to CMS, 2019-2025
24 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,039 · 2020: $1,055 · 2021: $1,304 · 2022: $1,898 · 2023: $1,787 · 2024: $1,785 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,362 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,362.30 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,031.74 | 2021-2025 | Saphnelo |
| Amgen INC. | $1,314.79 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Ucb, INC. | $1,307.97 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,231.79 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,126.82 | 2019-2022 | |
| Janssen Biotech, INC. | $1,074.47 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Horizon Therapeutics Plc | $774.76 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $583.20 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $507.40 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $289.59 | 2019-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $229.14 | 2021-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $198.85 | 2023-2025 | Idacio |
| Ani Pharmaceuticals, INC. | $176.39 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $171.37 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $157.94 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $114.97 | 2019 | |
| Genentech USA, INC. | $83.93 | 2019-2024 | Actemra |
| Pacira Therapeutics, INC. | $79.64 | 2019-2020 | |
| Intrafusion Gp, LLC | $59.09 | 2021 | |
| Sandoz INC. | $54.53 | 2025 | Hyrimoz |
| Genzyme Corporation | $29.38 | 2025 | |
| Sobi, INC | $27.89 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.32 | 2022 | |
| Celgene Corporation | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Leahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.